Pliant Therapeutics Provides Update on BEACON-IPF

About this update from Pliant Therapeutics, Inc.

[{"type":"image","alt":"Pliant Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Pliant Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/edb2ca8d16c72c342dd4b7660bdebe5e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0ysHvIhQdh.4yF4UgalK7A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/edb2ca8d16c72c342dd4b7660bdebe5e","width":300,"height":300}},"lazy":false},{"type":"text","content":"Bexotegrast development in IPF discontinued","length":43,"tagName":"p"},{"type":"text","content":"Clinical oncology program and early-stage programs continue","length":59,"tagName":"p"},{"type":"text","content":"Recent workforce and operational changes align with next steps","length":62,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF).","length":316,"tagName":"p"},{"type":"text","content":"BEACON-IPF Trial Update ","length":23,"tagName":"p"},{"type":"text","content":"BEACON-IPF was a randomized, double-blind, placebo-controlled, global Phase 2b/3 clinical trial evaluating patients with IPF. In March of this year, Pliant announced the voluntary discontinuation of BEACON-IPF following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, citing an imbalance in IPF-related adverse events.","length":457,"tagName":"p"},{"type":"text","content":"Following an analysis of the full safety and efficacy data from the BEACON-IPF trial, the Company is discontinuing development of bexotegrast in IPF. Results showed that at doses of 160 mg and 320 mg, bexotegrast demonstrated an unfavorable risk-benefit profile. Compared to placebo, bexotegrast-treated participants showed an increased risk of experiencing adverse events associated with IPF disease progression, defined as events of worsening of IPF and acute IPF exacerbation, respiratory-related hospitalization, and/or all-cause m...

More updates from Pliant Therapeutics, Inc.